APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Alzheimer's Disease Drug

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.

Selected research

Market Outlook & Growth Opportunities

Global Alzheimer's Disease Drug Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchAlzheimer's Disease Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Alzheimer's Disease Drug Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Alzheimer's Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alzheimer's Disease Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Alzheimer's Disease Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.

The major players in global Alzheimer’s Disease Drug market include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, etc. The top 3 players hold over 60% of global shares. Europe and North America are main markets, they occupy over 70% of the global market. Memantine and Donepezil are the main types, with a share about 70%. Early to Moderate Stages is the key application, which covers over 55% shares.

This report provides an overview of the global Alzheimer's Disease Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Alzheimer's Disease Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Alzheimer's Disease Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Alzheimer's Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Alzheimer's Disease Drug Segment by Company

Allergan

Eisai

Novartis

Daiichi Sankyo

Merz Pharma

Pfizer

Johnson & Johnson

Lundbeck

Alzheimer's Disease Drug Segment by Type

Donepezil

Memantine

Rivastigmine

Others

Alzheimer's Disease Drug Segment by Application

Early to Moderate Stages

Moderate to Severe Stages

Alzheimer's Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Alzheimer's Disease Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Alzheimer's Disease Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Alzheimer's Disease Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Alzheimer's Disease Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alzheimer's Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alzheimer's Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alzheimer's Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Alzheimer's Disease Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alzheimer's Disease Drug industry.

Chapter 3: Detailed analysis of Alzheimer's Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Alzheimer's Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Alzheimer's Disease Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Alzheimer's Disease Drug Industry Trends Table 2. Alzheimer's Disease Drug Industry Drivers Table 3. Alzheimer's Disease Drug Industry Opportunities and Challenges Table 4. Alzheimer's Disease Drug Industry Restraints Table 5. Global Alzheimer's Disease Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Alzheimer's Disease Drug Revenue Share by Company (2021-2026) Table 7. Global Alzheimer's Disease Drug Sales Volume by Company (M Units) & (2021-2026) Table 8. Global Alzheimer's Disease Drug Sales Volume Share by Company (2021-2026) Table 9. Global Alzheimer's Disease Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Alzheimer's Disease Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Alzheimer's Disease Drug Key Company Manufacturing Base & Headquarters Table 12. Global Alzheimer's Disease Drug Company, Product Type & Application Table 13. Global Alzheimer's Disease Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Alzheimer's Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Donepezil Table 18. Significant Companies of Memantine Table 19. Significant Companies of Rivastigmine Table 20. Significant Companies of Others Table 21. Global Alzheimer's Disease Drug Sales Volume by Type 2021 VS 2025 VS 2032 (M Units) Table 22. Global Alzheimer's Disease Drug Sales Volume by Type (2021-2026) & (M Units) Table 23. Global Alzheimer's Disease Drug Sales Volume by Type (2027-2032) & (M Units) Table 24. Global Alzheimer's Disease Drug Sales Volume Share by Type (2021-2026) Table 25. Global Alzheimer's Disease Drug Sales Volume Share by Type (2027-2032) Table 26. Global Alzheimer's Disease Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Alzheimer's Disease Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Alzheimer's Disease Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Alzheimer's Disease Drug Sales Value Share by Type (2021-2026) Table 30. Global Alzheimer's Disease Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Early to Moderate Stages Table 32. Significant Companies of Moderate to Severe Stages Table 33. Global Alzheimer's Disease Drug Sales Volume by Application 2021 VS 2025 VS 2032 (M Units) Table 34. Global Alzheimer's Disease Drug Sales Volume by Application (2021-2026) & (M Units) Table 35. Global Alzheimer's Disease Drug Sales Volume by Application (2027-2032) & (M Units) Table 36. Global Alzheimer's Disease Drug Sales Volume Share by Application (2021-2026) Table 37. Global Alzheimer's Disease Drug Sales Volume Share by Application (2027-2032) Table 38. Global Alzheimer's Disease Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Alzheimer's Disease Drug Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Alzheimer's Disease Drug Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Alzheimer's Disease Drug Sales Value Share by Application (2021-2026) Table 42. Global Alzheimer's Disease Drug Sales Value Share by Application (2027-2032) Table 43. Global Alzheimer's Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 44. Global Alzheimer's Disease Drug Sales by Region (2021-2026) & (M Units) Table 45. Global Alzheimer's Disease Drug Sales Market Share by Region (2021-2026) Table 46. Global Alzheimer's Disease Drug Sales by Region (2027-2032) & (M Units) Table 47. Global Alzheimer's Disease Drug Sales Market Share by Region (2027-2032) Table 48. Global Alzheimer's Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Alzheimer's Disease Drug Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Alzheimer's Disease Drug Sales Value Share by Region (2021-2026) Table 51. Global Alzheimer's Disease Drug Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Alzheimer's Disease Drug Sales Value Share by Region (2027-2032) Table 53. Global Alzheimer's Disease Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Alzheimer's Disease Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Alzheimer's Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (M Units) Table 56. Global Alzheimer's Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Alzheimer's Disease Drug Sales by Country (2021-2026) & (M Units) Table 58. Global Alzheimer's Disease Drug Sales Market Share by Country (2021-2026) Table 59. Global Alzheimer's Disease Drug Sales by Country (2027-2032) & (M Units) Table 60. Global Alzheimer's Disease Drug Sales Market Share by Country (2027-2032) Table 61. Global Alzheimer's Disease Drug Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Alzheimer's Disease Drug Sales Value Market Share by Country (2021-2026) Table 63. Global Alzheimer's Disease Drug Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Alzheimer's Disease Drug Sales Value Market Share by Country (2027-2032) Table 65. Allergan Company Information Table 66. Allergan Business Overview Table 67. Allergan Alzheimer's Disease Drug Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Allergan Alzheimer's Disease Drug Product Portfolio Table 69. Allergan Recent Development Table 70. Eisai Company Information Table 71. Eisai Business Overview Table 72. Eisai Alzheimer's Disease Drug Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Eisai Alzheimer's Disease Drug Product Portfolio Table 74. Eisai Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Alzheimer's Disease Drug Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Novartis Alzheimer's Disease Drug Product Portfolio Table 79. Novartis Recent Development Table 80. Daiichi Sankyo Company Information Table 81. Daiichi Sankyo Business Overview Table 82. Daiichi Sankyo Alzheimer's Disease Drug Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Daiichi Sankyo Alzheimer's Disease Drug Product Portfolio Table 84. Daiichi Sankyo Recent Development Table 85. Merz Pharma Company Information Table 86. Merz Pharma Business Overview Table 87. Merz Pharma Alzheimer's Disease Drug Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Merz Pharma Alzheimer's Disease Drug Product Portfolio Table 89. Merz Pharma Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Alzheimer's Disease Drug Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Pfizer Alzheimer's Disease Drug Product Portfolio Table 94. Pfizer Recent Development Table 95. Johnson & Johnson Company Information Table 96. Johnson & Johnson Business Overview Table 97. Johnson & Johnson Alzheimer's Disease Drug Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Johnson & Johnson Alzheimer's Disease Drug Product Portfolio Table 99. Johnson & Johnson Recent Development Table 100. Lundbeck Company Information Table 101. Lundbeck Business Overview Table 102. Lundbeck Alzheimer's Disease Drug Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Lundbeck Alzheimer's Disease Drug Product Portfolio Table 104. Lundbeck Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. Alzheimer's Disease Drug Distributors List Table 108. Alzheimer's Disease Drug Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Alzheimer's Disease Drug Product Image Figure 2. Global Alzheimer's Disease Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Alzheimer's Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Alzheimer's Disease Drug Sales (2021-2032) & (M Units) Figure 5. Global Alzheimer's Disease Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Alzheimer's Disease Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Donepezil Image Figure 10. Memantine Image Figure 11. Rivastigmine Image Figure 12. Others Image Figure 13. Global Alzheimer's Disease Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (M Units) Figure 14. Global Alzheimer's Disease Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Alzheimer's Disease Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Alzheimer's Disease Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Alzheimer's Disease Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Alzheimer's Disease Drug Sales Value Share by Type (2021-2032) Figure 19. Early to Moderate Stages Image Figure 20. Moderate to Severe Stages Image Figure 21. Global Alzheimer's Disease Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (M Units) Figure 22. Global Alzheimer's Disease Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Alzheimer's Disease Drug Sales Volume Share by Application (2021-2032) Figure 24. Global Alzheimer's Disease Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Alzheimer's Disease Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Alzheimer's Disease Drug Sales Value Share by Application (2021-2032) Figure 27. Global Alzheimer's Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (M Units) Figure 28. Global Alzheimer's Disease Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Alzheimer's Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Alzheimer's Disease Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Alzheimer's Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 32. North America Alzheimer's Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Alzheimer's Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Alzheimer's Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Alzheimer's Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Alzheimer's Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Alzheimer's Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 38. South America Alzheimer's Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Alzheimer's Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Alzheimer's Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Alzheimer's Disease Drug Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Alzheimer's Disease Drug Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Donepezil
  • Memantine
  • Rivastigmine
  • Others
Applications
  • Early to Moderate Stages
  • Moderate to Severe Stages
Companies covered
  • Allergan
  • Eisai
  • Novartis
  • Daiichi Sankyo
  • Merz Pharma
  • Pfizer
  • Johnson & Johnson
  • Lundbeck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Alzheimer's Disease Drug Sales Value (2021-2032)
  4. 1.2.2 Global Alzheimer's Disease Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Alzheimer's Disease Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Alzheimer's Disease Drug Market Dynamics
  1. 2.1 Alzheimer's Disease Drug Industry Trends
  2. 2.2 Alzheimer's Disease Drug Industry Drivers
  3. 2.3 Alzheimer's Disease Drug Industry Opportunities and Challenges
  4. 2.4 Alzheimer's Disease Drug Industry Restraints
3 Alzheimer's Disease Drug Market by Company
  1. 3.1 Global Alzheimer's Disease Drug Company Revenue Ranking in 2025
  2. 3.2 Global Alzheimer's Disease Drug Revenue by Company (2021-2026)
  3. 3.3 Global Alzheimer's Disease Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Alzheimer's Disease Drug Average Price by Company (2021-2026)
  5. 3.5 Global Alzheimer's Disease Drug Company Ranking (2024-2026)
  6. 3.6 Global Alzheimer's Disease Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Alzheimer's Disease Drug Company Product Type and Application
  8. 3.8 Global Alzheimer's Disease Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Alzheimer's Disease Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Alzheimer's Disease Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Alzheimer's Disease Drug Market by Type
  1. 4.1 Alzheimer's Disease Drug Type Introduction
  2. 4.1.1 Donepezil
  3. 4.1.2 Memantine
  4. 4.1.3 Rivastigmine
  5. 4.1.4 Others
  6. 4.2 Global Alzheimer's Disease Drug Sales Volume by Type
  7. 4.2.1 Global Alzheimer's Disease Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Alzheimer's Disease Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Alzheimer's Disease Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Alzheimer's Disease Drug Sales Value by Type
  11. 4.3.1 Global Alzheimer's Disease Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Alzheimer's Disease Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Alzheimer's Disease Drug Sales Value Share by Type (2021-2032)
5 Alzheimer's Disease Drug Market by Application
  1. 5.1 Alzheimer's Disease Drug Application Introduction
  2. 5.1.1 Early to Moderate Stages
  3. 5.1.2 Moderate to Severe Stages
  4. 5.2 Global Alzheimer's Disease Drug Sales Volume by Application
  5. 5.2.1 Global Alzheimer's Disease Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Alzheimer's Disease Drug Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Alzheimer's Disease Drug Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Alzheimer's Disease Drug Sales Value by Application
  9. 5.3.1 Global Alzheimer's Disease Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Alzheimer's Disease Drug Sales Value by Application (2021-2032)
  11. 5.3.3 Global Alzheimer's Disease Drug Sales Value Share by Application (2021-2032)
6 Alzheimer's Disease Drug Regional Sales and Value Analysis
  1. 6.1 Global Alzheimer's Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Alzheimer's Disease Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Alzheimer's Disease Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Alzheimer's Disease Drug Sales by Region (2027-2032)
  5. 6.3 Global Alzheimer's Disease Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Alzheimer's Disease Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Alzheimer's Disease Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Alzheimer's Disease Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Alzheimer's Disease Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Alzheimer's Disease Drug Sales Value (2021-2032)
  12. 6.6.2 North America Alzheimer's Disease Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Alzheimer's Disease Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Alzheimer's Disease Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Alzheimer's Disease Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Alzheimer's Disease Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Alzheimer's Disease Drug Sales Value (2021-2032)
  21. 6.9.2 South America Alzheimer's Disease Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Alzheimer's Disease Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Alzheimer's Disease Drug Sales Value Share by Country, 2025 VS 2032
7 Alzheimer's Disease Drug Country-level Sales and Value Analysis
  1. 7.1 Global Alzheimer's Disease Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Alzheimer's Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Alzheimer's Disease Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Alzheimer's Disease Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Alzheimer's Disease Drug Sales by Country (2027-2032)
  6. 7.4 Global Alzheimer's Disease Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Alzheimer's Disease Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Alzheimer's Disease Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Alzheimer's Disease Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Alzheimer's Disease Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Alzheimer's Disease Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Alzheimer's Disease Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Alzheimer's Disease Drug Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Eisai
  8. 8.2.1 Eisai Company Information
  9. 8.2.2 Eisai Business Overview
  10. 8.2.3 Eisai Alzheimer's Disease Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Alzheimer's Disease Drug Product Portfolio
  12. 8.2.5 Eisai Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Alzheimer's Disease Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Alzheimer's Disease Drug Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Daiichi Sankyo
  20. 8.4.1 Daiichi Sankyo Company Information
  21. 8.4.2 Daiichi Sankyo Business Overview
  22. 8.4.3 Daiichi Sankyo Alzheimer's Disease Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Daiichi Sankyo Alzheimer's Disease Drug Product Portfolio
  24. 8.4.5 Daiichi Sankyo Recent Developments
  25. 8.5 Merz Pharma
  26. 8.5.1 Merz Pharma Company Information
  27. 8.5.2 Merz Pharma Business Overview
  28. 8.5.3 Merz Pharma Alzheimer's Disease Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merz Pharma Alzheimer's Disease Drug Product Portfolio
  30. 8.5.5 Merz Pharma Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Alzheimer's Disease Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Alzheimer's Disease Drug Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Johnson & Johnson
  38. 8.7.1 Johnson & Johnson Company Information
  39. 8.7.2 Johnson & Johnson Business Overview
  40. 8.7.3 Johnson & Johnson Alzheimer's Disease Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Johnson & Johnson Alzheimer's Disease Drug Product Portfolio
  42. 8.7.5 Johnson & Johnson Recent Developments
  43. 8.8 Lundbeck
  44. 8.8.1 Lundbeck Company Information
  45. 8.8.2 Lundbeck Business Overview
  46. 8.8.3 Lundbeck Alzheimer's Disease Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Lundbeck Alzheimer's Disease Drug Product Portfolio
  48. 8.8.5 Lundbeck Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Alzheimer's Disease Drug Value Chain Analysis
  2. 9.1.1 Alzheimer's Disease Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Alzheimer's Disease Drug Sales Mode & Process
  6. 9.2 Alzheimer's Disease Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Alzheimer's Disease Drug Distributors
  9. 9.2.3 Alzheimer's Disease Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst